Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

11.08
-0.0100-0.09%
Post-market: 11.300.2200+1.99%19:52 EDT
Volume:3.05M
Turnover:34.28M
Market Cap:2.43B
PE:-7.84
High:11.49
Open:11.10
Low:10.94
Close:11.09
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:0.64
T/O Rate:1.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:4.66
PE(LYR):-7.80

Loading ...

Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset

TIPRANKS
·
Aug 17

Ocular Therapeutix rises 10.4%

TIPRANKS
·
Aug 17

Rival Ocular Therapeutix Shares up 8%

THOMSON REUTERS
·
Aug 17

Ocular Therapeutix Shares up 12.7% Premarket After Rival EyePoint's Eye Drug Misses Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Aug 17

Ocular Therapeutix Grants New SVP Beth Rada Options for 85,000 Shares, 28,000 RSUs Under Inducement Plan

Reuters
·
Aug 14

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 14

Ocular Therapeutix Grants Inducement Awards to New Hires, Including Options Priced at $8.4 Per Share

Reuters
·
Aug 08

Ocular Therapeutix™ Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 08

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 08

Tarsus Pharmaceuticals Q2 Sales Beat Estimates, Lifts 2026 Xdemvy Sales Outlook

Reuters
·
Aug 06

Viridian Therapeutics Q2 Net Loss Widens as Lumvoa Launch Lifts Costs

Reuters
·
Aug 06

RxSight Q2 Adjusted Loss Beats Estimates; Withdraws 2026 Guidance

Reuters
·
Aug 06

Sight Sciences Q2 Revenue Rises 20%, Beats Estimates

Reuters
·
Aug 06

Canada's Kits Eyecare Q2 Revenue Slightly Beats on Glasses Segment Growth

Reuters
·
Aug 05

EyePoint Pharmaceuticals Q2 Revenue Drops on Lower License Income

Reuters
·
Aug 05

Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says

MT Newswires Live
·
Aug 04

Palvella Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 04

Ocular Therapeutix Faces Governance and Perception Risks from Insider Equity Compensation and Trading Practices

TIPRANKS
·
Aug 04

Stoke Therapeutics Q2 Revenue Falls 33% on Lower Collaboration, Licensing Income

Reuters
·
Aug 04

Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Twist Bioscience (TWST)

TIPRANKS
·
Aug 04